Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Investigator: Chinemerem Abanonu, MD

Study Coordinator:

Status: Enrolling

ClinicalTrials.gov Number: NCT05633602

Phone:

Protocol Number: PRO00037682

Description

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent).
More to Explore